Novartis’ new heart failure medicine Sacubitril valsartan is now available in the UK
Sacubitril valsartan (Entresto™) is now available for UK adults with symptomatic chronic heart failure with reduced ejection fraction
Largest heart failure study showed Entresto (sacubitril valsartan) saves lives and reduces hospitalisation for people with heart failure when compared to enalapril, an ACE-inhibitor, and current gold standard, commonly used to treat the condition.
New treatments that can reduce hospitalisations and the number of people dying from heart failure are needed as the outlook for patients remains poor3
Heart failure costs the NHS £2.3 billion, and the figure is rising due to the UK’s ageing population
Entresto™ (sacubitril valsartan), a twice-a-day tablet for adult patients with symptomatic heart failure with reduced ejection fraction, is now available in the UK.
Heart failure occurs when the heart muscle cannot pump a normal amount of oxygen-rich blood around the body, resulting in a substantial impact on patients’ daily lives. The new treatment has been shown to save the lives of patients with heart failure when compared to the gold standard treatment, enalapril.
“The availability of this new treatment in heart failure could change how heart failure patients are treated,” said Professor Iain Squire, Professor of Cardiovascular Medicine, University of Leicester and Honorary Consultant Physician, University Hospitals of Leicester NHS Trust and Chair of British Society for Heart Failure.
“For many patients with heart failure, outcomes remain poor and there is clear room for therapies that improve on what we have available at the moment. Doctors can now offer suitable patients an option that has been shown in a large clinical trial to cut the risk of death and reduce the number of hospitalisations.”
Sacubitril valsartan works in a unique way by reducing the strain on the failing heart. In the largest heart failure clinical trial conducted to date, it reduced the risk of death from cardiovascular causes, such as sudden death and worsening heart failure, compared to enalapril, an ACE inhibitor. ACE inhibitors are the most commonly used treatment for heart failure.
Overall, sacubitril valsartan reduced the risk of death from heart-related causes or of first hospitalisation for heart failure by 20% when compared to enalapril (absolute risk reduction: 4.7%)2 . Patients on the trial were asked to report on how well they felt and the doctors caring for them how severe the patient’s heart failure was: patients taking sacubitril valsartan reported feeling better and having less severe symptoms in the sacubitril valsartan group compared to patients taking enalapril.
The clinical trial stopped early as it showed a clear benefit of sacubitril valsartan over enalapril.
“Patients with heart failure had a poor prognosis for many years, with survival rates being worse than certain types of cancer, such as breast and prostate,” said Dimitrios Georgiopoulos MD, Chief Scientific Officer, Novartis Pharmaceuticals UK Ltd. “Our clinical trial showed that treatment with sacubitril valsartan reduces the risk of death and hospitalisation for patients and the availability of this new treatment will give doctors a new option to manage many of their heart failure patients.”
On average, a general practitioner looks after 30 patients with heart failure and will diagnose ten new heart failure patients annually. However, despite being such a common condition, most people fail to recognise the symptoms. Common symptoms include difficulty breathing, swollen limbs due to build-up of fluid, severe fatigue and weight gain due to fluid build-up.
Heart failure is a highly debilitating, life-threatening condition, which affects around 550,000 people in the UK. Heart failure is a considerable burden to the UK healthcare system. It costs the NHS about £2.3bn a year, accounts for 1 million inpatient bed days and 5% of all emergency and medical admissions to UK hospitals; hospital admissions are projected to rise by 50% over the next 25 years, largely as a result of an ageing population.
Hospitalisation is costly and heart failure patients are frequently readmitted; 70% of treatment costs for heart failure are due to hospitalisations10 . Novartis is working with NICE and the Scottish Medicines Consortium (SMC) to ensure as many eligible patients as possible will be able to benefit from sacubitril valsartan once it has been appraised.
Sacubitril valsartan is a twice-a-day tablet. In its pivotal study, PARADIGM-HF which compared sacubitril/valsartan to enalapril, the risk of dying from a heart-related cause or being hospitalised for the first time in the trial because of heart failure was reduced by a fifth in patients taking sacubitril valsartan. Patients on sacubitril valsartan reported feeling better than patients receiving treatment with enalapril. Fewer patients on sacubitril valsartan discontinued study medication for any adverse event compared to those on enalapril. The sacubitril valsartan group had more hypotension and non-serious angioedema but less renal impairment, hyperkalemia and cough than the enalapril group .